Welcome to our dedicated page for Bionexus Gene La SEC filings (Ticker: BGLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how BioNexus Gene Lab Corp (BGLC) juggles regional chemical sales and RNA-based diagnostics can feel like reading two companies at once. Annual reports exceed 200 pages, and critical details—such as liquid biopsy trial milestones or composite material margin shifts—are scattered across exhibits. That’s why investors searching for "BioNexus Gene Lab insider trading Form 4 transactions" or "BioNexus Gene Lab quarterly earnings report 10-Q filing" land here first.
Stock Titan’s AI decodes every disclosure the moment it hits EDGAR. Our platform delivers real-time alerts for "BioNexus Gene Lab Form 4 insider transactions real-time," pinpoints R&D outlays in the 10-K, and summarises cash-flow swings in each 10-Q. Prefer plain language? Select "BioNexus Gene Lab SEC filings explained simply" and get concise briefs that clarify how 8-K material events—from new diagnostic approvals to supply-chain agreements—affect revenue. You’ll also find:
- Side-by-side analysis of chemical vs. healthcare segment revenue in the "BioNexus Gene Lab annual report 10-K simplified" view
- Instant email or Slack alerts on "BioNexus Gene Lab executive stock transactions Form 4" before markets open
- AI-highlighted sections of the proxy statement covering "BioNexus Gene Lab proxy statement executive compensation" and board independence
Whether you’re modelling earnings, assessing insider conviction, or simply "understanding BioNexus Gene Lab SEC documents with AI," our coverage is complete. Every 8-K, 10-Q, 10-K, S-1, or Form 4 is indexed, summarised, and linked to source PDFs so you can move from headline to footnote in a click. The result: "BioNexus Gene Lab earnings report filing analysis" delivered in minutes—not hours—letting you act on information instead of searching for it.
BioNexus Gene Lab Corp (BGLC) 10-Q excerpts show corporate and balance-sheet details without full financial statements. The company reports 300,000,000 shares authorized with 1,796,597 shares outstanding in one period and 1,796,766 shares outstanding at December 31, 2024 (post-reverse split basis). The company disclosed the 2017 acquisition of Bionexus Gene Lab Sdn. Bhd., later renamed MRNA Scientific Sdn. Bhd. It records trade receivables at invoiced amounts less an allowance for expected credit losses, writes off uncollectible accounts, and notes typical receivable terms range from 30 to 90 days. One customer was charged interest at 6% per annum through June 2023 and the rate increased to 8.4% from July 2023. The filing notes 1,044,351 shares issued due to a round-up and corporate governance actions at subsidiary Chemrex Corporation Sdn. Bhd., including additional directors, policy updates, and enhanced reporting to the company CFO and Audit Committee.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) filed an 8-K to disclose a Regulation FD communication. On 30 July 2025 the company signed a non-binding term sheet with Singapore-based Fidelion Diagnostics Pte Ltd. The parties are negotiating a cross-equity strategic alliance and have granted BGLC exclusive commercialization rights in Southeast Asia to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) testing platform, a precision-oncology technology aimed at detecting trace cancer cells post-treatment.
The agreement is still preliminary; no financial terms, timelines or definitive contracts were announced. The company framed the deal as a potential “DeepSeek Moment” for oncology diagnostics in the region. No guidance, revenue impact or financing details accompanied the disclosure, and the item is being furnished, not filed, so it carries no immediate accounting effect.
FAQ
What is the current stock price of Bionexus Gene La (BGLC)?
What is the market cap of Bionexus Gene La (BGLC)?
